Medical-device assessment bodies operate within designation and oversight arrangements, rather than simply declaring themselves qualified. In Great Britain, the MHRA assesses and monitors UK approved bodies. European notified bodies have their own designation framework. Venture investment does not replace those requirements, and commercial ownership alone does not establish that an assessment is either compromised or trustworthy.
Scarlet's October 2026 fundraise makes the governance question timely. The useful response is to examine how impartial assessment is maintained as an organisation grows, not to infer misconduct from its financing. This article considers public information checked on 13 October 2026 and proposes questions applicable across the sector.
Designation is a substantive starting point
The MHRA's January 2024 announcement explains that an approved body is assessed for impartiality, objectivity, competence, capacity and appropriate quality-management arrangements. It also describes continuing monitoring through audits and observation of some manufacturer audits.
That is more substantial than a private company issuing itself a badge. However, it is not a reason to stop asking which legal entity and activities are covered. The official approved-body list should be checked for the actual organisation, and the detailed scope should match the proposed device and route.
The European Commission's notified-body guidance describes a separate designation system. Readers should not blend the UK and European arrangements into an undifferentiated worldwide licence to certify AI.
Paying for assessment creates a tension to govern
An organisation may pay for an assessment without being entitled to a favourable decision. That distinction is fundamental to the service. Commercial responsiveness and impartial scrutiny should coexist, but they are not the same objective.
A hypothetical assessor could improve customer communication, reduce unnecessary waiting and organise submissions more efficiently while maintaining rigorous decisions. A different hypothetical arrangement could reward revenue growth without protecting the time needed for difficult cases. Neither pattern should be assumed from the ownership structure alone.
The governance question is how the organisation prevents financial interests from determining substantive findings. That includes the separation between selling an engagement, allocating suitably competent people, reviewing evidence and deciding what the evidence justifies.
Published controls deserve acknowledgement and examination
As checked on 13 October 2026, Scarlet's public information describes conflict-of-interest controls, an impartiality panel, complaints and appeals processes, and restrictions on providing consultancy to manufacturers seeking market release. These are published governance arrangements, not independently verified findings about their effectiveness.
A fair analysis should acknowledge those controls rather than imply they are absent. It should then ask how a prospective client or other stakeholder can understand the route for raising a concern and how decisions remain independent in practice.
The distinction is the same one applied to clinical AI products: a documented design or policy matters, but is not proof that every individual process works perfectly. Effective governance requires evidence of implementation, proportionate oversight and the ability to respond when problems are identified.
A sector-wide governance questionnaire
The following questions are an editorial proposal, not allegations about Scarlet or any other body.
| Governance topic | Question to ask | What an informative answer would explain |
|---|---|---|
| Commercial separation | Can sales commitments influence assessment findings? | Decision authority and boundaries between functions |
| Competence | How are reviewers assigned to unfamiliar clinical or technical work? | Relevant expertise, escalation and competence maintenance |
| Conflicts | How are financial or previous professional relationships handled? | Declaration, exclusion and reassignment processes |
| Growth | What happens when demand exceeds qualified capacity? | How work is paced without diluting necessary review |
| Challenges | How can a decision or process concern be challenged? | Distinct complaints and appeals routes |
| Oversight | Who can inspect the body's performance? | Applicable supervisory arrangements and cooperation |
A useful answer is specific enough to distinguish a policy from an aspiration. It does not need to disclose confidential client information to explain who holds authority and how a concern is managed.
Growth can strengthen capacity or expose weak controls
Venture-backed growth could support recruitment, training, better evidence systems and more consistent communication. Those are plausible benefits, not established outcomes of a particular investment.
Growth can also create pressures around utilisation, revenue targets and expansion into unfamiliar areas. The relevant test is whether an organisation builds competence before making commitments that depend on it. An enlarged service catalogue does not itself show that every area has sufficient specialist coverage.
Consider a fictional assessment team entering a new clinical specialty. A responsible plan might initially restrict the types of application accepted, use appropriately qualified reviewers and define when further expertise is needed. A less defensible plan would treat general AI familiarity as a substitute for understanding the particular clinical evidence.
The distinction concerns operational judgement, not whether the organisation is new or old. Established bodies can face commercial pressures too, while newer bodies can design robust protections.
Independence does not mean refusing useful communication
A manufacturer should be able to understand the process, the applicable scope and the meaning of assessment findings. Clear communication can reduce wasted work without telling the manufacturer how to obtain a predetermined outcome.
The boundary becomes important when an assessor is expected to design the product's evidence strategy and then independently judge its own advice. The appropriate arrangements depend on the applicable scheme and independence requirements; the roles should not be blurred merely for convenience.
For a founder, this creates a practical reason to distinguish regulatory or clinical safety advice from conformity assessment. An adviser can help make the evidence coherent. The assessment body must still reach its own conclusion through the relevant process.
What should investors and healthcare buyers monitor?
Our proposed investor questions concern the durability of the operating model: whether growth depends on shortcuts, whether expertise is retained and whether the business can withstand a necessary unfavourable decision. These are questions for diligence, not claims that certification demand guarantees attractive returns.
Healthcare buyers have a different task. They should verify the relevant assessment documents and their scope, then examine the evidence and local deployment conditions. The source of an assessor's capital should not replace that product-level work in either direction.
This article is published by iatroX, whose Insights service, described on 13 October 2026, includes clinical safety and readiness advice. That creates an advisory interest in the sector, not an independent certification role. Consultancy, assessment and regulatory oversight are most useful when their boundaries remain clear.
Frequently asked questions
Who oversees UK approved bodies for medical devices?
The MHRA designates and monitors UK approved bodies within the relevant framework. The legal entity and scope should be checked in official records.
Does venture capital make a certification body less independent?
Ownership alone does not establish that conclusion. The relevant questions concern impartiality controls, competence, decision authority and how commercial pressures are managed.
Is paying for an assessment the same as buying a certificate?
No. Payment covers an assessment service; a favourable outcome must depend on satisfying the applicable requirements rather than the client's commercial expectations.